Inspired by Passion

Developing Therapies to 

Transform

the Practice of Medicine

ABOUT US

Triursus Therapeutics is a cutting edge biotechnology company, spun out of technology and insights developed in Dr. Everett Meyer’s Lab at Stanford University in conjunction with our other world-class founders Rosemarie DeKruyff, Ph.D. and Gordon Freeman, Ph.D.
 
We’re developing novel monoclonal antibodies against several targets for the potential treatment of serious inflammatory diseases such as inflammatory bowel disease (IBD: Crohn disease and ulcerative colitis), graft-versus-host disease (GVHD), and others. 

OUR VISION

 

OUR VISION

OUR LEAD INDICATION UNDER DEVELOPMENT:
GVHD: GRAFT-VERSUS-HOST DISEASE 
We want to change the way transplant medicine is practiced, by transforming the way patients with serious hematologic malignancies are treated.  Despite the best current care, many patients undergoing a potentially curative transplant develop GVHD.  GVHD has a high rate of morbidity and mortality.  Because of this high unmet need, we founded Triursus Therapeutics to develop potential therapies for GVHD.  

Let doctors and patients focus on curing cancer, not battling GVHD
OTHER INDICATIONS UNDER DEVELOPMENT:
INFLAMMATORY BOWEL DISEASE (IBD) AND
OTHER DISEASES OF INFLAMMATION

We’re leveraging our unique insights on disease biology and pathophysiology to develop potential therapeutics to address other areas of high unmet need related to serious diseases of inflammation, including Crohn disease, ulcerative colitis, and other conditions.
 
 

LOOKING FOR A CAREER?  

We are a team of passionate people that are visionaries with a sharp focus on the details.  If you are interesting in learning more about how we are making a difference,  please contact us.

OUR TEAM

FOUNDERS and ADVISORS

Everett Meyer, M.D., Ph.D.
 (Founder, BOD)  
Medical & Scientific Director
Bone Marrow Transplantation,
Stanford University
Rosemarie DeKruyff, Ph.D.
(Founder, Advisor, BOD)
Professor, Stanford University
Advisor Sean Parker Inst.
Gordon Freeman, Ph.D. (Founder, Advisor)
Professor, Harvard University
Dana-Farber Cancer Institute
Kirk Essenmacher, M.D., M.B.A.         (CEO Triursus Therapeutics)  
Genentech, Alvine Pharmaceuticals, Abbott, Guidant Corporation
Hua Tu, Ph.D.
(Collaborator, BOD)
CEO, LakePharma
John “Lippy” Lippincott, Ph.D.
(Collaborator)
VP, AlivaMab Discovery Services

Want to learn more about our therapeutic focus?  Please fill in the following contact form:

 

CONTACT

Triursus Therapeutics

(born in Palo Alto)

© 2019 by Triursus Therapeutics